Treatment of mild persistent asthma

New England Journal of Medicine

Volumn 356, Issue 20, 2007, Pages 2096-2100

  Kraft, Monica ^a   Israel, Elliot ^b   O'Connor, George T ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; SALBUTAMOL; ANTIASTHMATIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; GLUCOCORTICOID; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

ADULT; ANAMNESIS; ASTHMA; CASE REPORT; CONSULTATION; DRUG RESPONSE; DRUG TOLERANCE; DYSPNEA; EXERCISE INTENSITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; NOTE; PRESCRIPTION; PRIORITY JOURNAL; SKIN TEST; SPIROMETRY; ARTICLE; DRUG ADMINISTRATION; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ALBUTEROL; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; LEUKOTRIENE ANTAGONISTS;

EID: 34249085720     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMclde078062     Document Type: Article

References (15)

1. The American Lung Association Asthma Clinical Research Centers. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med 2007;356:2027-39.
2. Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med 2007;356:2040-52.
3. Tattersfield AE, Harrison TW, Hubbard RB, Mortimer K. Safety of inhaled corticosteroids. Proc Am Thorac Soc 2004;1:171-5.
4. Boushey HA, Sorkness CA, King TS, et al. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005;352:1519-28.
5. Breekveldt-Postma NS, Gerrits CM, Lammers JW, Raaijmakers JA, Herings RM. Persistence with inhaled corticosteroid therapy in daily practice. Respir Med 2004;98:752-9.
6. National Asthma Education and Prevention Program. NAEPP Expert Panel report: guidelines for the diagnosis and management of asthma - update on selected topics 2002. Bethesda, MD: National Heart, Lung, and Blood Institute, 2002. (Publication no. 02-5075.)
7. Idem. National Asthma Education and Prevention Program. Expert Panel report: guidelines for the diagnosis and management of asthma: update on selected topics - 2002. J Allergy Clin Immunol 2002;110:Suppl 5:141S-219S.
8. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001;345:941-7.
9. Edelman JM, Turpin JA, Bronsky EA, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction: a randomized, double-blind trial. Ann Intern Med 2000;132:97-104.
10. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26. [Erratum, Chest 2006;129:1393.]
11. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Ann Intern Med 1999;130:487-95.
12. Zeiger RS, Bird SR, Kaplan MS, et al. Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: a randomized controlled trial. Am J Med 2005;118:649-57.
13. Ni Chroinin M, Greenstone IR, Danish A, et al. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst Rev 2005;4:CD005535.
14. Boulet LP. Once-daily inhaled corticosteroids for the treatment of asthma. Curr Opin Pulm Med 2004;10:15-21.
15. Ernst P, McIvor A, Ducharme FM, et al. Safety and effectiveness of long-acting inhaled beta-agonist bronchodilators when taken with inhaled corticosteroids. Ann Intern Med 2006;145:692-4.